Canadian Nuclear Laboratories and Canadian Commercial Corporation Sign Letter of Understanding to Cooperate on Global Expansion of Nuclear Energy
| RDY Stock | USD 12.78 0.17 1.31% |
Slightly above 62% of Dr Reddys' investor base is looking to short. The analysis of overall sentiment of trading Dr Reddys Laboratories stock suggests that many investors are alarmed at this time. Dr Reddys' investing sentiment can be driven by a variety of factors including economic data, Dr Reddys' earnings reports, geopolitical events, and overall market trends.
RDY |
Agreement comes as Canada works to strengthen nuclear partnerships in the Indo-Pacific region CANADIAN NUCLEAR LABORATORIES AND CANADIAN COMMERCIAL CORPORATION SIGN LETTER OF UNDERSTANDING TO COOPERATE ON GLOBAL EXPANSION OF NUCLEAR ENERGY CNL Vice-President of Corporate Affairs, Lou Riccoboni, and CCC Vice-President of Business Development and Marketing, Kim Douglas, celebrate the signing of a Letter of Understanding in Manilla as part of a Team Canada Trade Mission to Indonesia and the Philipp
Read at finance.yahoo.com
 |
Dr Reddys Fundamental Analysis
We analyze Dr Reddys' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Dr Reddys using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Dr Reddys based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Debt To Equity
Debt To Equity Comparative Analysis
Dr Reddys is currently under evaluation in debt to equity category among its peers. Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Dr Reddys Laboratories Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Dr Reddys stock to make a market-neutral strategy. Peer analysis of Dr Reddys could also be used in its relative valuation, which is a method of valuing Dr Reddys by comparing valuation metrics with similar companies.
Peers
Dr Reddys Related Equities
| ANIP | ANI Pharmaceuticals | 13.39 | ||||
| PAHC | Phibro Animal | 2.85 | ||||
| COLL | Collegium Pharmaceutical | 2.22 | ||||
| PBH | Prestige Brand | 1.22 | ||||
| SUPN | Supernus Pharmaceuticals | 0.94 | ||||
| ALKS | Alkermes Plc | 0.85 | ||||
| ITCI | Intracellular | 0.04 | ||||
| EVO | Evotec SE | 3.87 | ||||
| PCRX | Pacira BioSciences, | 5.24 |
Additional Tools for RDY Stock Analysis
When running Dr Reddys' price analysis, check to measure Dr Reddys' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dr Reddys is operating at the current time. Most of Dr Reddys' value examination focuses on studying past and present price action to predict the probability of Dr Reddys' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dr Reddys' price. Additionally, you may evaluate how the addition of Dr Reddys to your portfolios can decrease your overall portfolio volatility.